We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

A Study of QBI-139 in Subjects With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00818831
Recruitment Status : Unknown
Verified January 2015 by Quintessence Biosciences, Inc..
Recruitment status was:  Active, not recruiting
First Posted : January 8, 2009
Last Update Posted : January 28, 2015
Information provided by (Responsible Party):
Quintessence Biosciences, Inc.

Brief Summary:

The purposes of this trial are:

  • To evaluate the toxicity and tolerability of QBI-139 in patients with advanced refractory solid tumors.
  • To determine the maximum tolerated dose of QBI-139 in patients with advanced, refractory solid tumors.

Patients will receive QBI-139 by IV infusion over at least one hour once weekly for three weeks. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3 to 6 patients receive escalating doses of QBI-139 until the maximum tolerated dose (MTD) is determined.

Condition or disease Intervention/treatment Phase
Solid Tumors Drug: QBI-139 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Phase I Safety and Pharmacokinetic Study of QBI-139 Injection Administered by Weekly Intravenous Infusion in Patients With Refractory Malignancies
Study Start Date : January 2009
Estimated Primary Completion Date : October 2015

Intervention Details:
  • Drug: QBI-139
    QBI-139 is being administered once a week over a two hour infusion in escalating doses.

Primary Outcome Measures :
  1. To evaluate the toxicity and tolerability of and the maximum tolerated dose for QBI-139 in patients with advanced refractory solid tumors. [ Time Frame: Cycle 1 (three weeks) ]

Secondary Outcome Measures :
  1. To determine the patient response rate to QBI-139 using the RECIST criteria. [ Time Frame: Duration of drug administration ]
  2. To evaluate the pharmacokinetics of QBI-139 [ Time Frame: Cycles 1 and 2 (six weeks) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must be refractory to or intolerant of established therapy known to provide clinical benefit for their condition, i.e., patients must not be candidates for regimens known to provide clinical benefit.
  • Patients must have measurable (as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria) solid tumors.
  • Prior chemotherapy and radiation therapy are allowed (at least 4 weeks must have passed from prior chemotherapy and radiotherapy (6 weeks for nitrosoureas or mitomycin C)), provided that clinically significant toxicity related to prior chemotherapy or radiotherapy has returned to baseline or National Cancer Institute (NCI) Common Toxicity and Adverse Events (CTCAE) grade ≤ 2 and are not expected to recover further. The toxicities specifically exclude alopecia.
  • Age >18 years.
  • ECOG performance status <2.
  • Life expectancy of greater than 12 weeks, as estimated by Principal Investigator.
  • Patients must have normal organ and marrow function as defined in the protocol.
  • The effects of QBI-139 on the developing human fetus are unknown. Therefore, both men and women should not attempt to conceive and women should not be pregnant or breast-feeding while taking part in this study (or for 90 days after completing the study).
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Concurrent treatment with an investigational agent other than the investigational agent(s) used in this study OR treatment within 4 weeks of study entry with any investigational agent(s) or device(s).
  • Failure to recover fully (as judged by the Investigator) from prior surgical procedures.
  • Patients with known brain metastases or leptomeningeal carcinomatosis
  • Patients who have had a gastrointestinal bleed requiring transfusion within the past 6 months or active Grade 2 or higher diarrhea
  • Treatment with Ranpirnase (Onconase®)
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Women who are pregnant or breastfeeding
  • Patients known to have HIV are ineligible
  • Patients with known immunocompromised status or organ transplants will be excluded
  • Patients must not have:

    • unstable angina (anginal symptoms at rest) within the past 6 months or
    • myocardial infarction within the past 6 months or
    • new onset angina within the last 3 months.
  • QT prolongation (defined as QTc >450 msec for males and QTc >470 msec for females)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00818831

Layout table for location information
United States, Texas
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States
United States, Wisconsin
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
Quintessence Biosciences, Inc.
Additional Information:
Layout table for additonal information
Responsible Party: Quintessence Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT00818831    
Other Study ID Numbers: QBI-139 -101
CO 08912 ( Other Identifier: University of Wisconsin Comprehensive Cancer Center )
2009-0716 ( Other Identifier: MD Anderson )
First Posted: January 8, 2009    Key Record Dates
Last Update Posted: January 28, 2015
Last Verified: January 2015
Keywords provided by Quintessence Biosciences, Inc.:
Advanced, refractory solid tumors